PUMA BIOTECHNOLOGY, INC.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
PBYI$8.25-15.6%Stored close · as of Nov 6, 2026
Contents
Item 1. Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2026 and 2025
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenues: | ||||
| Product revenue, net | $53,560 | $49,188 | $95,519 | $92,292 |
| Royalty revenue | 2,942 | 3,248 | 5,797 | 6,151 |
| Total revenue | 56,502 | 52,436 | 101,316 | 98,443 |
| Operating costs and expenses: | ||||
| Cost of sales | 12,475 | 12,301 | 22,899 | 22,857 |
| Selling, general and administrative | 17,547 | 18,047 | 35,970 | 35,651 |
| Research and development | 18,895 | 15,452 | 38,690 | 29,315 |
| Total operating costs and expenses | 48,917 | 45,800 | 97,559 | 87,823 |
| Income from operations | 7,585 | 6,636 | 3,757 | 10,620 |
| Other income (expenses): | ||||
| Interest income | 831 | 956 | 1,833 | 2,057 |
| Interest expense | (180) | (1,837) | (911) | (4,014) |
| Other income | 9 | 410 | 139 | 769 |
| Total other income (expenses), net | 660 | (471) | 1,061 | (1,188) |
| Net income before income taxes | $8,245 | $6,165 | $4,818 | $9,432 |
| Income tax expense | (56) | (310) | (382) | (603) |
| Net income | $8,189 | $5,855 | $4,436 | $8,829 |
| Net income per share of common stock—basic | $0.16 | $0.12 | $0.09 | $0.18 |
| Net income per share of common stock—diluted | $0.16 | $0.12 | $0.08 | $0.18 |
| Weighted-average shares of common stock outstanding—basic | 50,939,946 | 49,700,217 | 50,892,800 | 49,648,246 |
| Weighted-average shares of common stock outstanding—diluted | 52,596,589 | 50,144,704 | 52,278,925 | 50,003,709 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.